live in maternal mental health professional shortage areas
this not only leaves mothers with no treatment options, but is also commonly noted by health insurance plans as the reason for their insufficient provider networks
A rule or plan of action, adopted and followed by a group, organization, or government
We are a policy think tank and field catalyst. We inform and facilitate systems change to improve women’s mental health during the childbearing years so that mothers, children, and families have the best opportunity to thrive.
To date, U.S. adoption of DTX has been slow due to limited insurance reimbursement structures, lack of integration into healthcare systems, and low patient awareness. That’s a challenge because DTX could significantly impact healthcare by offering patients non-pharmaceutical alternative treatment options that can be more efficiently monitored and providing economic benefits for providers by introducing new and more frequent billing opportunities….
On Wednesday, December 4, the Policy Center presented an Axios media event titled “Improving Postpartum Care” in the U.S. Here are our CEO, Joy Burkhard’s remarks, including a question and answer that didn’t make it into the segment. …
It’s been a year since Zurzuvae™, the first oral postpartum depression drug treatment, became FDA-approved. Initially, very few insurers/payers had published coverage guidelines. Now nearly all have published guidelines, and most provide reasonable access to Zurzuvae….
In 2024, Reunion Neuroscience announced the launch of phase 2 of the RECONNECT clinical trial, a psychedelic treatment for postpartum depression (PPD). The clinical trial began in July of this year and the trial is expected to end in 2025. …